AnaptysBio, Inc. cash flow to debt ratio of 139.58% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

AnaptysBio, Inc.'s free cash flow has increased -114.45% from $-135.69M last year to $19.61M, signaling increasing performance

AnaptysBio, Inc.'s debt to equity ratio is 21.76, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

AnaptysBio, Inc.'s debt has increased relative to shareholder equity from 5.21 last year to 21.76 today, signaling weakened financials

AnaptysBio, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

AnaptysBio, Inc.'s interest coverage ratio is 0.49, which means that the company struggles to meet interest obligations, signaling financial risk.

AnaptysBio, Inc.'s profit margin has increased (-92.76%) in the last year from -159.10% to -11.53%, signaling increasing performance

AnaptysBio, Inc.'s short-term assets of $350.25M exceed its short-term liabilities of $38.62M

AnaptysBio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

AnaptysBio, Inc.'s return on equity of 442.91%, is higher than 15.00%, indicating good performance

AnaptysBio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

AnaptysBio, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

AnaptysBio, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

AnaptysBio, Inc. has a free cash flow yield of 0.73%, which is below the 2.00% threshold, indicating limited cash return relative to market value

AnaptysBio, Inc.'s yearly earnings has increased -90.89% since last year from $-145.23M to $-13.23M, signaling increasing performance

AnaptysBio, Inc.'s yearly revenue has increased 157.01% since last year from $91.28M to $234.60M, signaling increasing performance

ROIC 14.06% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

AnaptysBio, Inc.'s 3-year revenue CAGR of 183.58% is positive, indicating growing revenue over the past 3 years

AnaptysBio, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

AnaptysBio, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

AnaptysBio, Inc. has insufficient data to evaluate this check.

AnaptysBio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AnaptysBio, Inc. is overvalued relative to its fair value price of 20.05 based on EBITDA multiple model

AnaptysBio, Inc. has an EV/EBITDA ratio of 35.69x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

AnaptysBio, Inc. is overvalued relative to its fair value price of -182.44 based on Earnings Fair Value model

AnaptysBio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AnaptysBio, Inc. has a price-to-book ratio of 140.69x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

AnaptysBio, Inc. has a price-to-sales ratio of 7.72x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue